ReviewCurrent infectious disease reports2020
Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.
Review in Current infectious disease reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Carbapenem-resistant Enterobacterales bacteraemia at a tertiary hospital: A five-year review.Southern African journal of infectious diseases · 2026Article
- Rapid and high-sensitivity quantitative fluorescent immunoassay for detection ofFrontiers in microbiology · 2026Article
- Molecular epidemiology and mechanisms ofFrontiers in microbiology · 2026Article
- Challenges of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales.Antibiotics (Basel, Switzerland) · 2025Article
- Antibacterial and cytotoxic activities of different solvent extracts fromContemporary oncology (Poznan, Poland) · 2025Article
- Susceptibility of various Gram-negative bacteria to antibacterial agents: SMART in China 2019-2020.BMC microbiology · 2024Article
- Molecular characterization and descriptive analysis of carbapenemase-producing Gram-negative rod infections in Bogota, Colombia.Microbiology spectrum · 2024Article
- Anti-MRSA and cytotoxic activities of different solvent extracts fromOpen veterinary journal · 2024Article
- Diverse Role ofAntibiotics (Basel, Switzerland) · 2024Article
- Clinical and epidemiological characteristics of multi-drug resistantJournal of medicine and life · 2024Article
- Specificity and mechanism of TonB-dependent ferric catecholate uptake by Fiu.Frontiers in microbiology · 2024Article
- Article
- Evaluation of the BD Phoenix CPO Detect Panel for Detection and Classification of Carbapenemase ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Evaluation of the NG-Test CARBA 5 Lateral Flow Assay with an IMP-27-Producing Morganella morganii and OtherMicrobiology spectrum · 2023Article
- Epidemiology of Resistance Determinants Identified in Meropenem-NonsusceptibleAntimicrobial agents and chemotherapy · 2023Article
- The Behavior of Some Bacterial Strains Isolated from Fallow Deer Compared to Antimicrobial Substances in Western Romania.Antibiotics (Basel, Switzerland) · 2023Article
- The Clash of the Titans: COVID-19, Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- CRISPR-Cas System: A Tool to Eliminate Drug-Resistant Gram-Negative Bacteria.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Comparative effectiveness of antibiotic therapy for carbapenem-resistant Enterobacterales (CRE) bloodstream infections in hospitalized US veterans.JAC-antimicrobial resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGram-negative resistance is a growing concern globally. Enterobacterales, formerly Enterobacteriaceae, have developed resistance mechanisms to carbapenems that leave very few antimicrobial options in the clinician's armamentarium. RECENT
findingsNew antimicrobials like ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, and plazomicin have the potential to overcome resistance mechanisms in Enterobacterales including different classes of carbapenemases. Novel β-lactam/β-lactamase inhibitors, plazomicin, and cefiderocol give the clinician options that were once not available. Utilizing these options is of the utmost importance when treating carbapenem-resistant Enterobacterales.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.